Premium
The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.
Author(s) -
Begg EJ,
Robson RA,
Ikram H,
Richards AM,
BammertAdams JA,
Olson SC,
Posvar EL,
Reece PA,
Sedman AJ
Publication year - 1994
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1994.tb04280.x
Subject(s) - quinapril , ejection fraction , heart failure , medicine , pharmacokinetics , renal function , cardiology , dosing , creatinine , ace inhibitor , angiotensin converting enzyme , blood pressure
The pharmacokinetics of quinapril and its active metabolite quinaprilat were studied in 12 patients with congestive heart failure (CHF) after multiple oral doses of 10 mg quinapril twice daily. Six patients had an ejection fraction of < 35% and six had an ejection fraction between 35%‐ 50%. Increases in the apparent elimination half‐life and in AUC(0, 12h) values of quinaprilat were associated with smaller ejection fractions, decreased creatinine clearance, and increased patient age. Comparison with data from age‐matched controls having comparable renal function suggests that creatinine clearance is the major determinant of quinaprilat clearance. CHF per se appears to have minimal effect. Dosing of quinapril in patients with CHF should be based on their renal function.